France In Vitro Diagnostics (IVD) Quality Control Market (2025-2030)
The France In Vitro Diagnostics (IVD) Quality Control Market was valued at $69.4 Million in 2025 and projected to reach to $93.9 Million by 2030, representing a compound annual growth rate of 6.2%. France's IVD Quality Control Market demonstrates robust growth potential, driven by the country's advanced healthcare infrastructure and commitment to diagnostic precision.
France In Vitro Diagnostics (IVD) Quality Control Market Trends and Insights
- France's market growth is driven by stringent regulatory requirements, increasing adoption of advanced diagnostic technologies, and rising demand for laboratory automation across French healthcare institutions.
- The French market benefits from strong healthcare infrastructure and significant investment in diagnostic quality assurance standards. The expansion of France's IVD quality control sector reflects broader European trends toward enhanced laboratory standardization and compliance with ISO and CE marking requirements.
- France's diagnostic laboratories and clinical centers are increasingly implementing sophisticated quality control solutions to ensure accuracy and reliability of test results.
- Between 2025 and 2030, France is expected to see accelerated adoption of digital quality control platforms and real-time monitoring systems, positioning the country as a key market within the European IVD landscape..
Key Market Statistics
- CAGR (2025-2030) 6.2% CAGR
- Market Size, 2025 ~USD 69.4 Million
- Forecast, 2030 ~USD 93.9 Million
- Country France
France In Vitro Diagnostics (IVD) Quality Control Market Overview
Market Valuation :
France's IVD Quality Control Market is valued at USD 69.4 million in 2025, with strong growth trajectory driven by healthcare modernization and diagnostic advancement across the country.
Regulatory Compliance Drivers :
Stringent EU and French regulatory requirements mandate rigorous quality control standards in diagnostic laboratories, creating sustained demand for advanced QC solutions and compliance infrastructure.
Laboratory Automation Adoption :
French healthcare facilities are increasingly investing in laboratory automation technologies to enhance diagnostic accuracy, reduce turnaround times, and optimize operational efficiency in clinical settings.
Growth Projection :
The market is forecasted to reach USD 93.9 million by 2030, representing a CAGR of 6.2%, outpacing the global growth rate of 5.5% and reflecting France's commitment to diagnostic excellence.
France In Vitro Diagnostics (IVD) Quality Control Market Dynamics
- The market benefits from stringent EU regulatory frameworks that mandate comprehensive quality assurance protocols, positioning France as a leader in diagnostic standardization across Europe.
- Increasing investments in laboratory modernization and the adoption of automated quality control systems are reshaping the competitive landscape. Looking ahead, France's market will be shaped by technological innovation, including AI-powered quality monitoring and real-time data analytics.
- The integration of digital health initiatives and the expansion of point-of-care testing networks will create new opportunities for QC solution providers.
- Strategic partnerships between diagnostic manufacturers and French healthcare institutions will further accelerate market penetration and drive sustainable growth through 2030..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- JOHNSON & JOHNSON
Key Takeaways
- France's IVD Quality Control Market is valued at USD 69.4 million in 2025 and will reach USD 93.9 million by 2030, growing at 6.2% CAGR.
- France's stringent regulatory environment and ISO compliance requirements drive demand for advanced quality control solutions in diagnostic laboratories.
- Digital transformation and laboratory automation are accelerating adoption of real-time quality control monitoring systems across French healthcare facilities.
- France's strong healthcare infrastructure and investment in diagnostic standardization position it as a leading IVD quality control market in Europe.
In Vitro Diagnostics (IVD) Quality Control Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MOLECULAR DIAGNOSTICS (Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.5% from 2025 to 2030 |
| Largest Segment | QUALITY CONTROL PRODUCTS (Product & Service) |
| Market Size Base Year (Billions) | ~USD 1.65 (2025) |
| Revenue Forecast (Billions) | ~USD 2.15 (2030) |
| Segments Covered | Product & Service, Type, Technology, Manufacturer Type, End User |
France In Vitro Diagnostics (IVD) Quality Control Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product & Service
- Data Management Solutions
- Quality Assurance Services
- Quality Control Products
By Type
- Independent Controls
- Instrument-Specific Controls
- Other Controls
- Serum/Plasma-Based Controls
- Urine-Based Controls
- Whole Blood-Based Controls
By Technology
- Clinical Chemistry
- Coagulation & Hemostasis
- Hematology
- Immunoassays
- Microbiology
- Molecular Diagnostics
- Other Technologies
By Manufacturer Type
- Original Equipment Manufacturer Controls
- Third-Party Controls
By End User
- Academic & Research Institutes
- Clinical Laboratories
- Hospitals
- Other End Users
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers need France-specific market data to develop localized product strategies, understand regulatory requirements, and identify opportunities for laboratory automation solutions aligned with French healthcare standards.
- Quality Control Solution Providers : QC solution vendors require detailed insights into France's compliance landscape, customer preferences, and competitive dynamics to optimize market positioning and drive adoption of advanced quality assurance technologies.
- Healthcare Investment Firms : Investment professionals need comprehensive France market analysis to evaluate growth potential, identify acquisition targets, and make informed capital allocation decisions in the diagnostic sector.
- Laboratory Management Consultants : Consultants advising French healthcare institutions require market intelligence on automation trends, regulatory compliance pathways, and best practices to guide laboratory modernization initiatives.
- Healthcare Policy & Regulatory Bodies : French healthcare authorities and regulatory agencies need market data to inform policy development, quality standards, and strategic initiatives supporting diagnostic excellence and patient safety.
Key Companies in the France In Vitro Diagnostics (IVD) Quality Control Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Clinical microbiology (VITEK, culture media, ID/AST, BACT/ALERT),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS),Immunoassays and biomarkers (VIDAS, Hybiome CLIA, sepsis markers), |
| CEPHEID INC. | United States | Private Company | GeneXpert instruments and Xpert test cartridges,SmartCycler systems and assays,Collaborative and program-based solutions (e.g., TB, Ebola, USPS BDS), |
| IMMUCOR, INC. | United States | Private Company | Transfusion (serology instruments and reagents),Transplant & Molecular (HLA, HEA/HPA typing, Array Imaging System),Platelet-focused and specialty coagulation products, |
| DIASORIN | Italy | Public Company | Immunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers, |
| UNILABS | Switzerland | Private Company | Core laboratory testing,Medical imaging services,Pathology and centres of excellence, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Reagents,Other and Services, |
| THERMO FISHER SCIENTIFIC, INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ABBOTT | United States | Public Company | Diagnostic Products (core lab, rapid, molecular, cardiometabolic, drug testing),Medical Devices (cardiovascular, diabetes care, neuromodulation),Nutritional Products (pediatric, adult, infant formula), |
| LGC LIMITED | South Korea | Public Company | Ethylene-based synthetic resins (EVA, HDPE, LDPE, LLDPE, POE, metallocene PE, UNIQABLE),Styrene-based resins (ABS, ASA, EPS, PS, SAN),Polycarbonate and polypropylene, |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| QUIDELORTHO CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care (professional and OTC), |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation systems and reagents,Blood gas, electrolyte, and urinalysis analyzers, |
| BIO-TECHNE CORPORATION | United States | Public Company | Protein Sciences reagents (cytokines, growth factors, antibodies, small molecules, sera, cell selection),Proteomic and protein analysis instruments and immunoassays,Diagnostics products, controls, calibrators, and assays, |
| MICROBIX BIOSYSTEMS INC. | Canada | Public Company | Antigen and test ingredient business,QAPs branded test controls and quality assessment products,DxTM viral transport medium, |
| GRIFOLS, S.A. | Spain | Public Company | Biopharma (plasma-derived medicines),Diagnostic,Bio Supplies, |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company operates in the diagnostics and life sciences sector.
CEPHEID INC.
Cepheid Inc. is a private company founded in 1996 in the United States with 1,700 employees. The company specializes in molecular diagnostics and infectious disease testing.
IMMUCOR, INC.
Immucor, Inc. is a private company founded in 1982 in the United States with 1,125 employees. The company focuses on blood bank and transfusion diagnostics.
DIASORIN
DiaSorin is an Italian public company founded in 1968 with 3,242 employees. The company operates in the in vitro diagnostics sector.
UNILABS
Unilabs is a private company founded in 1987 in Switzerland with 1,897 employees. The company provides laboratory and diagnostic services.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures life science research and clinical diagnostics products.
THERMO FISHER SCIENTIFIC, INC.
Thermo Fisher Scientific, Inc. is a public company founded in 1956 in the United States with 125,000 employees. The company is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.
ABBOTT
Abbott is a public company founded in 1888 in the United States with 115,000 employees. The company operates in diagnostics, medical devices, pharmaceuticals, and nutritional products.
LGC LIMITED
LGC Limited is a public company founded in 1947 in South Korea with 14,019 employees. The company provides testing, proficiency testing, and reference materials services.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a public company founded in 1896 in Germany with 72,369 employees. The company provides medical imaging, laboratory diagnostics, and point-of-care testing solutions.
QUIDELORTHO CORPORATION
QuidelOrtho Corporation is a public company founded in 1979 in the United States with 6,500 employees. The company develops and manufactures rapid diagnostic tests and molecular testing solutions.
DANAHER CORPORATION
Danaher Corporation is a public company founded in 1969 in the United States with 59,000 employees. The company operates across diagnostics, life sciences, and environmental and applied solutions segments.
SYSMEX CORPORATION
Sysmex Corporation is a public company founded in 1968 in Japan with 10,861 employees. The company manufactures hematology analyzers and other in vitro diagnostic systems.
BIO-TECHNE CORPORATION
Bio-Techne Corporation is a public company founded in 1976 in the United States with 3,100 employees. The company develops and manufactures life science tools and bioanalytical instruments.
MICROBIX BIOSYSTEMS INC.
Microbix Biosystems Inc. is a public company founded in 1988 in Canada with 100 employees. The company produces quality control materials and reference standards for diagnostics.
GRIFOLS, S.A.
Grifols, S.A. is a public company founded in 1909 in Spain with 25,000 employees. The company specializes in blood plasma derivatives and diagnostic products.
Reasons to Buy this Report
- Localized Market Intelligence : Gain France-specific insights into market dynamics, regulatory landscape, and competitive positioning that directly impact investment and expansion decisions in the French diagnostic sector.
- Growth Opportunity Identification : Identify high-potential segments within France's 6.2% CAGR market growth, including emerging technologies and underserved laboratory automation niches with significant revenue potential.
- Regulatory Compliance Roadmap : Understand France's stringent EU-aligned regulatory requirements and quality control standards essential for market entry, product development, and successful commercialization strategies.
- Competitive Benchmarking : Analyze France-specific competitive positioning, market share distribution, and strategic initiatives of key players to inform competitive strategy and differentiation approaches.
- Strategic Planning & Forecasting : Leverage accurate 2025-2030 market projections and trend analysis for France to develop informed business strategies, resource allocation, and long-term growth planning in this expanding market.
Frequently asked questions
What is the current market size of IVD Quality Control in France?
France's IVD Quality Control Market is valued at USD 69.4 million in 2025 and is projected to grow to USD 93.9 million by 2030.
What is the expected growth rate for France's IVD Quality Control Market?
France's IVD Quality Control Market is expected to grow at a CAGR of 6.2% from 2025 to 2030.
What factors are driving growth in France's IVD Quality Control Market?
Key drivers include stringent regulatory requirements, increasing laboratory automation, rising demand for diagnostic accuracy, and compliance with ISO and CE marking standards across French healthcare institutions.
Which segments are leading France's IVD Quality Control Market?
France's market is led by segments focused on laboratory automation, digital quality control platforms, real-time monitoring systems, and compliance management solutions for diagnostic laboratories.
How does France's IVD Quality Control Market compare to other European markets?
France's 6.2% CAGR positions it as a strong performer within Europe, driven by robust healthcare infrastructure, regulatory rigor, and significant investment in diagnostic standardization and quality assurance.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global IVD quality controls market.
Exhaustive secondary research was done to collect information on the IVD quality controls market. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the IVD quality controls market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. Here’s the breakdown of tiers: Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the IVD quality controls market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
IVD quality controls are standardized materials used to monitor, evaluate, and ensure the accuracy, reliability, and precision of diagnostic testing processes in clinical laboratories. These controls are designed to mimic patient samples and are produced from human-derived matrices such as serum, plasma, urine, or whole blood. IVD quality controls provide a benchmark for validating test system performance, detecting errors, and ensuring regulatory compliance across diverse diagnostic platforms.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global IVD quality controls market by product & service, technology, manufacturer type, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall IVD quality controls market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the IVD quality controls market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full In Vitro Diagnostics (IVD) Quality Control Market Report
Full forecast, segment splits, and company analysis for all In Vitro Diagnostics (IVD) Quality Control Market.
- Canada In Vitro Diagnostics (IVD) Quality Control Market
- US In Vitro Diagnostics (IVD) Quality Control Market
- Germany In Vitro Diagnostics (IVD) Quality Control Market
- UK In Vitro Diagnostics (IVD) Quality Control Market
- Italy In Vitro Diagnostics (IVD) Quality Control Market
- Spain In Vitro Diagnostics (IVD) Quality Control Market
- Russia In Vitro Diagnostics (IVD) Quality Control Market
- China In Vitro Diagnostics (IVD) Quality Control Market
- Japan In Vitro Diagnostics (IVD) Quality Control Market
- India In Vitro Diagnostics (IVD) Quality Control Market
- Australia In Vitro Diagnostics (IVD) Quality Control Market
- South Korea In Vitro Diagnostics (IVD) Quality Control Market
- Brazil In Vitro Diagnostics (IVD) Quality Control Market
- Mexico In Vitro Diagnostics (IVD) Quality Control Market
- Saudi Arabia In Vitro Diagnostics (IVD) Quality Control Market
- UAE In Vitro Diagnostics (IVD) Quality Control Market
- Rest Of Europe In Vitro Diagnostics (IVD) Quality Control Market
- Rest Of Asia Pacific In Vitro Diagnostics (IVD) Quality Control Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report